Literature DB >> 3972334

Prolactin levels in pregnancy: comparison of normal subjects with patients having micro- or macroadenomas after early bromocriptine withdrawal.

N J Woodhouse, N Niles, D McDonald, S McCorkell.   

Abstract

14 previously infertile patients, 11 with radiologically abnormal fossae, and a mean prolactin level of 761 ng/ml (range 49-4,500 ng/ml) conceived on 19 occasions during bromocriptine treatment. So far, 15 healthy infants have been delivered. Treatment was withdrawn soon after conception and the subsequent prolactin changes compared with those of 44 normal subjects. Prolactin levels returned to pretreatment values in 7, but stayed within our normal range (less than 350 ng/ml) in the 6 remaining patients studied. No patient developed signs or symptoms of tumor enlargement. 2 patients, 1 of them with the largest tumor, have now normal prolactin levels and can be considered as cured. Bromocriptine treatment can restore fertility and be safely withdrawn during pregnancy even in patients presenting with large tumors. Nevertheless, patients should be carefully monitored and treatment with bromocriptine re-introduced if necessary.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972334     DOI: 10.1159/000180019

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

1.  Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.

Authors:  M M Garcia; L P Kapcala
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

2.  Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation.

Authors:  J Drewe; N Mazer; E Abisch; K Krummen; M Keck
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Treatment of hyperprolactinemia: a systematic review and meta-analysis.

Authors:  Amy T Wang; Rebecca J Mullan; Melanie A Lane; Ahmad Hazem; Chaithra Prasad; Nicola W Gathaiya; M Mercè Fernández-Balsells; Amy Bagatto; Fernando Coto-Yglesias; Jantey Carey; Tarig A Elraiyah; Patricia J Erwin; Gunjan Y Gandhi; Victor M Montori; Mohammad Hassan Murad
Journal:  Syst Rev       Date:  2012-07-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.